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Tear proteome analysis in ocular 
surface diseases using label-free 
LC-MS/MS and multiplexed-
microarray biomarker validation
Javier Soria1, Arantxa Acera1, Jesús Merayo-LLoves2, Juan A. Durán3,4, Nerea González1, 
Sandra Rodriguez1, Nikitas Bistolas5, Soeren Schumacher5, Frank F. Bier5, Harald Peter5, 
Walter Stöcklein5 & Tatiana Suárez1
We analyzed the tear film proteome of patients with dry eye (DE), meibomian gland dysfunction 
(MGD), and normal volunteers (CT). Tear samples were collected from 70 individuals. Of these, 37 
samples were analyzed using spectral-counting-based LC-MS/MS label-free quantitation, and 33 
samples were evaluated in the validation of candidate biomarkers employing customized antibody 
microarray assays. Comparative analysis of tear protein profiles revealed differences in the expression 
levels of 26 proteins, including protein S100A6, annexin A1, cystatin-S, thioredoxin, phospholipase 
A2, antileukoproteinase, and lactoperoxidase. Antibody microarray validation of CST4, S100A6, and 
MMP9 confirmed the accuracy of previously reported ELISA assays, with an area under ROC curve (AUC) 
of 87.5%. Clinical endpoint analysis showed a good correlation between biomarker concentrations 
and clinical parameters. In conclusion, different sets of proteins differentiate between the groups. 
Apolipoprotein D, S100A6, S100A8, and ceruloplasmin discriminate best between the DE and CT 
groups. The differences between antileukoproteinase, phospholipase A2, and lactoperoxidase levels 
allow the distinction between MGD and DE, and the changes in the levels of annexin A1, clusterin, and 
alpha-1-acid glycoprotein 1, between MGD and CT groups. The functional network analysis revealed 
the main biological processes that should be examined to identify new candidate biomarkers and 
therapeutic targets.
DE and MGD diseases involve the disruption of the lacrimal functional unit, resulting in symptoms of discomfort 
and visual disturbance and tear film instability. These illnesses may exist independently as either symptomatic or 
asymptomatic disorder; however, they are frequently found in the same patient. The progression of these diseases 
typically leads to alterations in the tear film and tear hyperosmolarity1 and the secretion of inflammatory media-
tors into the tears, initiated by cytokine release and metalloproteinase activation2. Ocular dryness disorders also 
promote squamous metaplasia (SM), mainly as a consequence of inflammation3, whose severity can be used for 
grading different diseases affecting the ocular surface4,5.
Tear film proteomics offers powerful analytical tools for studying the proteins involved in ocular diseases. 
Using these tools, we might be able to establish the precise functions of these proteins in the underlying patho-
physiological processes and provide diagnostics biomarkers. The studies of differential protein expression in 
complex biofluids such as tear film require rapid, highly reproducible, and accurate quantification. These require-
ments can be satisfied by mass spectrometry-based analysis6. Label-based mass spectrometry techniques have 
been employed to analyze the tear film, mainly by using isobaric tags for relative and absolute quantitation 
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(iTRAQ)7–10. However, label-free shotgun proteomics techniques are becoming increasingly popular since they 
are faster and supply cleaner and simpler results than the label-based techniques6. One of the most used label-free 
methods is spectral counting of identified proteins. This method is based on the fact that the number of spectra 
corresponding to peptides originating from a given protein shows a good linear correlation with the abundance 
of that protein11–14. Nevertheless, count ratios can be biased because of particular physiochemical properties 
of peptides or sampling issues in Data-Dependent Acquisition (DDA) shotgun procedure that may affect their 
detection by MS. As not all peptides can be perfectly ionized, appropriate measurement corrections should be 
applied to obtain accurate data15,16.
To date, several proteomic techniques have been applied to study variations in tear proteome caused by patho-
logical conditions and/or medical treatments. Many MS-based proteomic studies of tear film have been carried 
out using iTRAQ7–10, label-free14,17–19, SELDI-TOF20, or MALDI-TOF21–23 analysis. However, the results have 
been, at times, conflicting. Some of the studies have demonstrated changes in the expression of several proteins. 
Overexpression has been reported for protein ANXA114,23–25, S100A97,14,24,25, S100A87,14,20,23–25, and S100A47,24 
and downregulation, for prolactin-inducible protein (PIP)7,8,24–26, lactotransferrin (LT)7,8,14,24,27, proline-rich pro-
tein 4 (PRP4)8,14,20,25,26, lysozyme (LYZ)7,8,14,20,25,27, and cystatin-S (CST4)8,14,24,25, among others. Nevertheless, the 
changes in the expression of some proteins remain controversial. For example, several studies20,27 have demon-
strated upregulation of lipocalin-1 (LCN1), but its downregulation has been shown in others7,8,24,28. Similarly, con-
flicting results have been reported for other proteins such as secretoglobin 2A28,26,28 and serum albumin14,20,26–28. 
These discrepancies might have been caused by several factors such as different sample collection methods or 
sensitivity and dynamic range of the employed quantitation techniques29,30. Therefore, more extensive tear pro-
teome studies focusing on systems biology, supported by orthogonal validation assays, are needed to extract 
meta-information common to all these studies. The results of such studies should reduce the technological and 
experimental bias and improve our knowledge of the role of relevant proteins in the pathophysiology of ocular 
surface-related disorders.
We have previously characterized tear film proteomes and identified biomarkers for the aqueous-deficient dry 
eye (ADDE) and MGD, the main cause of evaporative DE (EDE) condition31, using 2D gel-based proteomics24.
The purpose of the present study was to identify proteins that can be used for discrimination between DE and 
MGD pathologies. To achieve this, we performed a quantitative differential study of tear protein expression using 
LC-MS/MS spectral-counting quantitative proteomics. Three candidate biomarkers were validated employing an 
orthogonal technique (customized microarray assays) using independent DE and CT tear samples.
Materials and Methods
Patients. A retrospective case-controlled study was carried out, in which 70 patients were enrolled. The 
experimental design consisted of a discovery phase (including 7 DE patients, 12 chronic MGD patients, and 18 
CT individuals for biomarker candidate selection), and a validation phase, for which 24 DE patients and 9 CT 
individuals were recruited (Fig. 1).
This research was conducted by medically qualified personnel after approval by the Cruces Hospital and 
the Principado de Asturias Hospital Ethics Committees. Approval was obtained in strict accordance with the 
Figure 1. Workflow overview. A general workflow outlining the steps used in the study for the identification 
of proteins deregulated in DE and MGD tear samples, using LC-MS/MS label-free quantitative proteomics, 
candidate biomarkers validation, and clinical correlation strategy.
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tenets of the Declaration of Helsinki on Biomedical Research Involving Human Subjects. Patients were recruited 
at the Instituto Clínico Quirúrgico de Oftalmología (Bilbao, Bizkaia, Spain) and the Instituto Universitario 
Fernández-Vega (Oviedo, Asturias, Spain). Before tear collection, the signed informed consent was obtained from 
all patients, once the nature and possible consequences of the study had been explained. The diagnosis was based 
on clinical examination including the Schirmer I test with anesthesia to measure the basal secretion, slit-lamp 
examination of the lid margin and Meibomian glands, fluorescein staining results according to Oxford scale, and 
subjective symptoms. Each patient answered the OSDI questionnaire, which included some statements about the 
quality of their vision and wellbeing.
Patients were classified as having DE if they had dry eye symptoms, dynamics abnormalities in Schirmer I test 
(≤5 mm/5 min), characteristic fluorescein staining of the corneal epithelium, and a tear breakup time (TBUT) 
≥5 s. MGD was diagnosed if the patients had eyelid inflammation, Schirmer I test results >5 mm/5 min, TBUT 
<5 s and alterations in Meibomian glands. Healthy subjects in the CT group were not suffering from any ocular 
disease (no allergic or atopic history). They presented Schirmer I test values >5 mm/5 min, TBUT >5 s, no cor-
neal fluorescein staining or sensations of discomfort, and no evident eyelid inflammation. The individuals with 
(or history of) any systemic or ocular disorder or condition (including ocular surgery, trauma, and disease) and 
patients with Sjögren’s syndrome were excluded. Contact lens users were also excluded to avoid any possible 
interference with the interpretation of the results.
Clinical evaluation of patients and sample collection. The order of tests and sample collection was 
always the same. First, the OSDI questionnaire was conducted to assess the symptoms of ocular irritation and 
their effect on the vision-related function. Second, one drop of topical anesthetic was applied to the ocular surface 
and the Schirmer I and fluorescein tests were performed. The tear samples and conjunctival impression cytology 
samples were collected one day later to avoid the interference between clinical tests and the proteomic study.
All tear samples were collected using calibrated 10-µl glass microcapillary tubes (BLAUBRAND intraMark, 
Wertheim, Germany). Tear samples were obtained from the inferior temporal tear meniscus, minimizing irri-
tation of the ocular surface or lid margin, without anesthesia. After collection, the tear samples were placed in 
Eppendorf tubes and stored at −80 °C until analysis. Protein quantification was performed using the EZQ Protein 
Quantification Kit (Invitrogen Dynal AS, Oslo, Norway).
To evaluate the degree of damage of the conjunctival epithelium (by examining the extent of SM), conjuncti-
val impression cytology (CIC) samples were obtained for PAS-hematoxylin staining. To achieve this, 5 × 5-mm 
membranes of cellulose acetate (HAWP304, Millipore, Bedford, MA, USA) were applied to the bulbar superior 
conjunctival epithelium following topical anesthesia (Colircusi double anesthetic, Alcon Cusí, Barcelona, Spain). 
The samples were immediately fixed in 96% ethanol and stained with PAS-hematoxylin, as previously described32. 
The samples were later examined under a light microscope to evaluate the grade of SM33. The cytoplasmic and 
nuclear areas of non-secretory cells, cytoplasmic alterations and staining, nuclear alterations, the nuclear to cyto-
plasmic area ratio (N:C ratio), and the number of goblet cells were examined.
Tear protein digestion, LC-MS/MS, and protein identification. To digest the proteins, RapiGest SF 
(Waters, Milford, MA, USA) was added to 4 µg of total tear protein at a concentration of 0.25% (w/v), and the 
mixture was heated at 85 °C for 15 min with agitation. Proteins were reduced (5 mM dithiothreitol, 60 °C, 25 min), 
alkylated (15 mM iodoacetamide, room temperature, 30 min), and digested with trypsin (0.2 µg, 37 °C, overnight; 
Roche Diagnostics, Penzberg, Germany). Finally, RapiGest SF was inactivated following the manufacturer’s 
instructions.
LC-MS/MS analysis was performed in a nanoACQUITY UPLC system interfaced to a SYNAPT HDMS mass 
spectrometer (Waters Corporation, Milford, MA). An aliquot of 1 µg of protein from each sample was loaded 
onto a Symmetry 300 C18, 180 µm × 20 mm precolumn (Waters Corporation, Milford, MA, USA) and washed 
with 0.1% formic acid for 3 min at a flow rate of 5 µl/min. The precolumn was connected to a BEH130 C18, 
75 µm × 200 mm, 1.7 µm (Waters Corporation, Milford, MA, USA), equilibrated in 3% acetonitrile with 0.1% 
formic acid. Peptides were directly eluted with a 120-min linear gradient of 3–60% acetonitrile onto a homemade 
nanoESI emitter. Data-dependent MS/MS acquisitions were performed on the 3 most intense precursors per 
scan, with charge states of 2, 3, or 4 over a survey m/z range of 400–1990 and a dynamic peak exclusion of 30 s. 
Collision energies were varied as a function of the m/z and charge state of each peptide. [Glu1]-fibrinopeptide B 
(Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 100 fmol/ml was sprayed through the NanoLockSpray 
source and sampled every 30 s. The obtained spectra were processed using VEMS34 and searched using MASCOT 
version 2.2.03 (Matrix Science, London, UK) against the UniProtKB/Swiss-Prot (version 2015_12) database, 
using only Homo sapiens entries. For protein identification, the following parameters were adopted: carbami-
domethylation of cysteines as fixed modification, oxidation of methionines as variable modification, peptide mass 
tolerance of 50 ppm, fragment mass tolerance of 0.1 Da, and 1 missed cleavage.
Quantitative protein analysis using spectral counting (APEX quantitation). Protein quantita-
tion was performed using label-free spectral counting, employing APEX Quantitative Proteomics Tool v.1.1 as 
described previously35. MASCOT output files were converted to the pepXML format using Trans-Proteomic 
Pipeline software v. 3.2.2 (Institute for Systems Biology, Seattle, WA)36. The resulting pepXML files were analyzed 
using PeptideProphet37. Subsequently, ProteinProphet38 was employed to assemble peptides into protein identi-
fication groups. Only proteins with ProteinProphet probability ≥ 0.95 and at least two identified peptides with a 
PeptideProphet probability ≥ 0.95 were reported. A probability-based penalty for peptide detection was applied, 
given that some peptides are detected by MS more readily than others. APEX quantitation analysis involves 
three steps. In step 1, a classification model is built, based on physiochemical properties of the peptide sequence 
(peptide mass, length, amino acid composition, properties related to charge, hydrophobicity, and amino acid 
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frequencies within the secondary peptide structures). The model is used to estimate MS-detectability (O(i)) for 
any given protein. Step 2 uses spectral count information to obtain absolute abundances of proteins in each MS/
MS experiment, corrected by applying an MS-detectability correction factor. Step 3 allows statistical significance 
analysis of differential expression in distinct biological samples. The protein false discovery rate was set at 1%; 
only proteins identified at a 99% confidence level were used for spectral counting.
Statistics. Data matrix obtained from APEX quantitation was used for multivariate statistical analysis. Before 
statistical analysis, protein expression data were filtered by considering only the proteins identified in at least 
50% of biological samples. K-nearest neighbor data imputation was performed to complete the data matrix and 
manage missing values imposed by intrinsic sampling issues in DDA shotgun approaches. Data were then nor-
malized using total spectral count normalization to reduce run-to-run variation39. Once the data matrix had been 
prepared for analysis, feature subset subtraction was performed by stepwise discriminant analysis with a p-value 
cutoff of 0.01, to obtain the most significant attributes defining each group. This process extracts the information 
that contributes most to the discrimination between groups. To reduce the dimensionality of the dataset for 
2D-visualization including the possible overlap between the groups, sample clustering was performed (using an 
exploratory data technique, the canonical discriminant analysis). Normalization, imputation, feature subset, and 
clustering analysis were carried out using R-Package v2.15.240.
Functional network analysis. Once the most significant tear proteins had been identified by LC-MS/MS 
analysis, the list of the most significantly upregulated or downregulated proteins was loaded into Cytoscape v. 
2.8.341 using Reactome Functional Interaction Network Cytoscape plugin42, to find network patterns related to 
diseases. The Cytoscape plugin accesses the Reactome Functional Interaction Network database. This database 
extends curated pathways with non-curated sources of information, including protein–protein interactions, 
gene coexpression, protein domain interaction, Gene Ontology (GO) annotations, and text-mined protein 
interactions. The process obtains a biological network based on the experimentally found proteins and the 
directly related proteins required to connect them in a network. With this information, functional interaction 
sub-networks (modules) were constructed. Then, the analysis of network modules of highly interacting groups of 
proteins and the functional enrichment and pathway analysis were performed. To select the biological processes 
and/or pathways that are predominant in each of the modules, we filtered the functional enrichment results using 
a false discovery rate cutoff value of 0.01. Finally, the Hubba Cytoscape Plugin43 was applied to the functional 
interaction subnetwork to find the most important nodes/hubs within the network. Topological analyses were 
performed using the Edge Percolated Component ranking method to evaluate node essentiality.
Validation of candidate biomarkers using antibody microarray assays. Three proteins with signif-
icant associations in mass spectrometry and network analysis (S100A6, CST4, and MMP9) were evaluated using 
customized sandwich-like antibody microarrays. The process of customized microarray preparation for quan-
titative tear biomarker analysis included several steps. These were i) identification of compatible antibody pairs 
for each biomarker and selection of high-affinity pairs by surface plasmon resonance (SPR) and sandwich ELISA 
assays, ii) evaluation of cross-reactivity between components in the multiplexed immunoassay, iii) determination 
of detection limits for each biomarker, iv) integration into the microarray platform and technical validation, and 
v) measurement of biomarker concentration in the selected tear samples (for validation purposes).
Briefly, mouse monoclonal antibodies against the selected proteins were spotted on 3D-epoxy-activated glass 
slides and cyclo-olefin polymer slides (PolyAn GmbH, Berlin, Germany) with the non-contact spotter sciFLEX-
ARRAYER S11 (Scienion AG, Berlin, Germany), in a 12-subarray format. Each antibody was spotted 20 times 
to reduce the technical variability. The nozzle used was PDC90, and a voltage of 82 V was applied, with a pulse 
width of 46 µs, loading a final volume of 1.5 nl/spot. The arrays were blocked with TBS-T supplemented with 
BSA (1%) for 1 hour. Antigens S100A6, CST4, and MMP9 were incubated for 1 h to obtain a standard curve from 
0.195 to 166 ng/ml. The reaction volume was 70 µl/well for all the steps in the immunoassay. Tear samples were 
diluted (1/30) in PBS for microarray analysis. Subsequently, the samples were incubated for 1 h with rabbit detec-
tion antibodies. Finally, after washing the slides with TBS-T, the secondary Alexa Fluor 647-labeled anti-rabbit 
antibodies were added and incubated for 1 h. Fluorescence of the spots was measured using a Tecan LS Reloaded 
Microarray Scanner (Tecan Deutschland GmbH, Crailsheim, Germany) at 633 nm, and protein concentration 
was determined based on standard curve intensity values.
After testing for normal distribution, significant differences between the groups were determined using 
Kruskal–Wallis non-parametric test. Once the concentration of each protein had been obtained, ROC curve 
analysis was performed, using logistic regression. The classification algorithm was trained using the biomarker 
panel, and to assess learner performance, a 10-fold random sampling was carried out with 70% of the samples as a 
training set. The remaining 30% of the samples constituted a test set. Statistical analysis was carried out using the 
Orange Canvas statistics package, version 2.6 (http://orange.biolab.si/). Finally, the Pearson correlation analysis 
was performed to assess correlations between clinical parameters and protein levels. The statistical analysis was 
conducted using R statistical program40.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Results
Patients. The patients recruited for the study were grouped into two sub-study groups, for discovery and 
validation. In the first group (37 volunteers), tear proteomics and CIC analyses were conducted. Demographical 
and clinical data for the discovery phase are presented in Table 1.
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We followed the recommendations for tests appropriate for diagnosis and assessment of the target ocular 
surface diseases studied here, DE and MGD44. Various diagnostic tests were used, depending on the objective. 
Thus, in the first part of the study (biomarker candidate selection), we analyzed patients with DE and MGD. We 
used the symptoms as a screening tool (OSDI), tear volume assessment to ascertain the subtype classification of 
DE (Schirmer test), and damage to the ocular surface (impression cytology) as a standard test to study squamous 
metaplasia and goblet cell density of the conjunctiva. In the second part of the study (the validation of candidate 
biomarkers), we assessed the DE patients and CT subjects; we employed the recommended diagnostic tests for 
DE44. Following the clinical protocol proposed for DE diagnosis, a broad range of diagnostic tests was performed, 
including OSDI (ocular surface symptoms), TBUT (tear film stability), Schirmer I test (tear volume), and fluo-
rescein staining (damage to the ocular surface). This was also done to determine the correlation matrix for bio-
marker concentrations and clinical parameters.
PAS-hematoxylin impression cytology revealed that in control samples, 72% of individuals (13/18) presented 
grade 0 SM (G0), whereas the remaining 28% (5/18) showed grades 1–2 (Table 1). In the MGD group, 17% of 
patients (2/12) had SM of grade 0, whereas mild grades (G1 and G2) were seen in 50% (6/12), and moderate (G3) 
to severe (G4) grades in 33% of patients (4/12). In the DE group, a mild grade of SM was found in 57% of patients 
(4/7), while the remaining 43% of DE patients exhibited moderate (G3) and severe (G4) grades. Schirmer test 
results showed significant differences (p-value < 0.05) between the groups, with values of 1.7, 8.0, and 13.8 for the 
DE, MGD, and CT groups, respectively. Mean age differences between the groups were not statistically significant 
(p-value > 0.05).
In the second part of the study, tear samples from 33 patients were analyzed on microarrays for validation 
purposes. To evaluate the correlation between biomarkers and clinical parameters, OSDI, TBUT, Schirmer I test, 
and fluorescein staining results were obtained for each patient in this phase of the study. All these parameters dif-
fered significantly between DE and CT individuals. The mean values for each parameter are presented in Table 2.
Quantitative protein analysis using spectral counting. Quantitative LC-MS/MS spectra analysis of 
tear proteome was performed computationally using the adjusted spectral counting method.
The analysis identified 603 significantly distinct proteins, by filtering the data to a minimum of two peptides 
identified with a PeptideProphet probability of 0.9 and a ProteinProphet probability of 0.95. However, as only 
the proteins identified in at least 50% of the samples were considered, this number was reduced to 135 proteins.
Protein expression data for those 135 proteins were used in further analysis. Model-based data imputation 
was performed to complete the data matrix and manage missing values. To establish which proteins were char-
acteristic for each pathological condition, a subtraction of expression data, using stepwise discriminant analysis 
modeling, was performed. As a result, we obtained a list of 26 specific proteins that undergo expression changes, 
achieving an effective discrimination between the groups (Table 3).
The clearest discrimination between the groups could be obtained by examining the expression of the follow-
ing proteins (overexpressed in the DE group): complement C3 (C3), protein S100-A6 (S100A6), protein S100-A8 
(S100A8), ceruloplasmin (CP), apolipoprotein D (APOD), alpha-1-acid glycoprotein 2 (ORM2), thioredoxin 
(TXN), Ig gamma-1 (IGHG1), membrane-associated phospholipase A2, (PLA2G2A), alpha-1-antitrypsin 
(SERPINA1), and antileukoproteinase (SLPI). Of these proteins, TXN, IGHG1, PLA2G2A, SERPINA1, and SLPI 
showed the lowest levels of expression in the MGD group, while the remaining proteins had the lowest expression 
in the control group. Similarly, in the MGD group, we found overexpression of the following proteins: annexin-A1 
(ANXA1), clusterin (CLU), alpha-1-acid glycoprotein 1 (ORM1), and lactoperoxidase (LPO). LPO was the most 
downregulated protein in the DE group. Finally, this analysis also revealed, both in the DE and MGD groups, 
reduced expression of several proteins. These were proline-rich protein 1 (PROL1), secretoglobin family 1D mem-
ber 1 (SCGB1D1), mammaglobin-B (SCGB2A1), lipocalin-1 (LCN1), cystatin-S (CST4), prolactin-inducible pro-
tein (PIP), dermcidin (DCD), submaxillary gland androgen-regulated protein 3B (PROL3), galectin-3-binding 
protein (LGALS3BP), extracellular glycoprotein lacritin (LACRT), and proline-rich protein 4 (PRR4). The lowest 
Group n Gender (M/F) Age Schirmer I test
Squamous metaplasia grade
0 1 2 3 4
CT 18 8/10 44.6 ± 21.4 13.8 ± 3.5 13 4 1 0 0
MGD 12 5/7 54.7 ± 11.6 8.0 ± 2.2 2 4 2 2 2
DE 7 2/5 56.1 ± 14.8 1.7 ± 2.0 0 1 3 2 1
Table 1. Demographic and clinical data of patients included in the discovery phase of the study. CT = Control; 
MGD = Meibomian gland dysfunction; DE = Dry eye.
Group n Gender (M/F) Age OSDI TBUT Schirmer I test Fluorescein staining
CT 9 3/6 36.78 ± 20.41 2.39 ± 2.45 13.39 ± 5.97 18.06 ± 5.85 0.33 ± 0.50
DE 24 10/14 54.58 ± 21.55 35.92 ± 19.37 6.21 ± 3.51 5.58 ± 5.30 1.50 ± 1.25
Table 2. Demographic and clinical data of patients included in the validation phase of the study. CT = Control; 
DE = Dry eye.
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levels of expression of these proteins were found in the DE group. For each protein, Table 3 lists fold-changes and 
the groups with its highest and lowest expression values.
Using data mining techniques, we also evaluated the spatial separation that these proteins are capable of pro-
ducing in the three tested groups. We used the expression data of the 26 proteins in the canonical discriminant 
analysis. We found a good separation between the experimental groups, reflecting the discriminative power pre-
sented by this list of proteins. However, it should be noted that there was a larger spatial separation between the 
DE and control group than between MGD and control (Fig. 2).
Functional interaction networks. The Cytoscape Reactome Functional Interaction Network plugin 
was used to find network patterns by accessing the Reactome Functional Interaction Network database. The 
disease-related network consisted of 19 of the candidate proteins associated with the diseases, found in this study, 
and the minimum number of interacting proteins necessary to interconnect them in a network (Fig. 3). Once the 
network had been constructed, functional clustering was performed using the same Cytoscape plugin. Cluster 
construction was based on proximity between the nodes. Five topologically well-differentiated modules were 
obtained (modules 1 to 5), comprising 11, 11, 15, 4, and 4 proteins, respectively. Functional enrichment analyses 
were then performed for each module to determine the biological processes involved in the pathologies, in rela-
tion to the structure of the network. With a false discovery rate cutoff of 0.01, we found statistically significant 
biological processes in 4 of the 5 modules. As illustrated in Table 4, module 1 of the network mainly represents the 
processes such as inflammatory response, regulation of chemokine production, response to lipopolysaccharide, 
cytokine-mediated signaling pathway, apoptotic signaling, acute-phase response, cell redox homeostasis, innate 
and humoral immune response, regulation of JNK cascade, and cellular defense response. Module 2 was princi-
pally formed by proteins involved in the extracellular matrix organization, collagen catabolic process, response to 
cytokine stimulus, angiogenesis, aging, response to hypoxia, regulation of cell proliferation, and neutrophil chem-
otaxis. Module 3 was made up of proteins significantly related to the defense response to bacteria and positive reg-
ulation of the inflammatory response. Module 4 was related to signal transduction, regulation of apoptosis, and 
fibroblast proliferation processes. Module 5 did not show significant relationships with any biological processes.







P01024 Complement C3 C3 5.66E-05 1.86 DE CT 6
P06703 Protein S100-A6 S100A6 5.40E-08 2.26 DE CT 2
P05109 Protein S100-A8 S100A8 1.68E-04 2.15 DE CT 4
P00450 Ceruloplasmin CP 3.76E-02 3.25 DE CT 2
P05090 Apolipoprotein D APOD 8.68E-03 3.85 DE CT 3
P19652 Alpha-1-acid glycoprotein 2 ORM2 1.69E-04 2.13 DE CT 4
P10599 Thioredoxin TXN 4.14E-04 1.61 DE MGD 3
P01857 Ig gamma-1 chain C region IGHG1 4.14E-04 1.61 DE MGD 10
P14555 Phospholipase A2, membrane-associated PLA2G2A 1.77E-02 3.13 DE MGD 7
P01009 Alpha-1-antitrypsin SERPINA1 4.05E-03 1.98 DE MGD 5
P03973 Antileukoproteinase SLPI 2.32E-02 3.59 DE MGD 3
P04083 ANXA1 protein ANXA1 1.46E-03 1.83 MGD CT 2
P10909 Clusterin CLU 1.52E-02 2.68 MGD CT 8
P02763 Alpha-1-acid glycoprotein 1 ORM1 1.75E-02 1.49 MGD CT 4
P22079 Lactoperoxidase LPO 1.73E-02 2.40 MGD DE 2
Q99935 Proline-rich protein 1 PROL1 5.82E-03 1.64 CT DE 8
O95968 Secretoglobin family 1D member 1 SCGB1D1 2.00E-02 1.63 CT DE 5
O75556 Mammaglobin-B SCGB2A1 3.56E-03 1.65 CT DE 11
P31025 Lipocalin-1 LCN1 3.61E-02 1.81 CT DE 11
P01036 Cystatin-S CST4 3.56E-03 1.65 CT DE 6
P12273 Prolactin-inducible protein PIP 3.69E-02 1.9 CT DE 8
P81605 Dermcidin DCD 6.27E-03 2.55 CT DE 2
P02814 Submaxillary gland androgen-regulated protein PROL3 3.44E-02 1.61 CT DE 4
Q08380 Galectin-3-binding protein LGALS3BP 4.61E-02 2.64 CT DE 2
Q9GZZ8 Extracellular glycoprotein lacritin LACRT 2.19E-02 1.83 CT DE 6
Q16378 Proline-rich protein 4 PRR4 3.23E-02 2.02 CT DE 4
Table 3. Proteins identified by LC-MS/MS with the most significant changes in their expression levels in dry 
eye (DE), Meibomian gland dysfunction (MGD), and control (CT) groups. The fold-values shown for each 
protein refer to the ratios between the group with the highest mean expression values (Highest Mean) and the 
group with the lowest mean expression values (Lowest Mean). The number of peptides identified was filtered 
using the PeptideProphet probability threshold of 0.95. FDR = False discovery rate.
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Finally, to find the most significant nodes in the network, the BisoGenet plugin was applied to the network. 
This plugin generates numerical and graphical output, making it easy to find the key nodes in the complex net-
works. This analysis can provide biologically meaningful node identification and functional classification by iden-
tifying the major nodes, the so-called “hub nodes,” which have many incoming and/or outgoing connections 
within a network. As a result, we found that the proteins MMP9, JUN, RELA, STAT3, TLR4, ESR1, GNAI3, 
ANXA1, and TIMP1 were the hub nodes of the functional interaction network. These proteins are involved in 
inflammation, adherens junction process, signaling pathways, cell–cell communication, and signal transduction.
Figure 2. Canonical Discriminant Analysis results showing the separation between the samples as a function 
of the values for the 26 discriminant proteins obtained by stepwise discriminant analysis. Each of the points 
represents a sample from each group. Good separation between the groups is apparent. The MGD group was 
closer to the control group (CT) than the DE group. Key: squares, CT group; triangles, MGD group; circles, DE 
group.
Figure 3. The functional interaction network obtained using the Functional Interaction Reactome Cytoscape 
plugin41. Proteins in the interaction network are represented as nodes (red dashed-line circles), while the 
interaction between any two proteins is represented by a line. These interactions can be direct (physical) and/or 
indirect (functional) in nature. Node colors indicate different modules obtained by topological clustering of the 
network using the functional interaction clustering method.
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Validation of candidate biomarkers using microarray assays. To validate further the relative protein 
expression data of tear proteins biomarkers obtained via MS-based spectral-counting techniques, we employed 
an orthogonal technique based on antibody microarrays, using an independent group of DE and control samples. 
The S100A6 and CST4 proteins, significantly deregulated according to the results of the LC-MS/MS analysis, were 
selected for validation. The MMP9 protein, inferred from network analysis, was also used in this validation. The 
antibody microarray assays confirmed significant changes in CST4 and S100A6 levels seen in LC-MS/MS assays. 
They also corroborated the network analysis inference of the implication of MMP9 in the DE disease (Fig. 4). The 
results showed that the tear concentrations of S100A6 (p-value = 0.0008) and MMP9 (p-value = 0.0097) were sig-
nificantly higher in the DE group in comparison with the control group, confirming the mass spectrometry find-
ings. However, the CST4 level was significantly lower in the DE group than in the CT group (p-value = 0.0028) 
(Fig. 5). The ratios between the DE and CT group for S100A6, MMP9, and CST4 were 2.67, 2.48, and −1.59, 
respectively.
In addition, we used these three markers to generate multivariate predictive models. To this end, we performed 
training employing random sampling with 70% of the data and a logistic regression algorithm. Subsequently, the 
classifier method was validated using the remaining 30% of data. The results showed an AUC value of 87.5% 
(Fig. 5D).
Correlation of validated tear biomarkers with clinical endpoints. The data obtained for proteins 
S100A6, CST4, and MMP9 were used to assess the correlation between the biomarkers and clinical parameters. 
A post-hoc Pearson correlation analysis was performed to determine whether the individual protein levels were 
associated with the tested clinical parameters (Schirmer I test, TBUT, OSDI, fluorescein staining, and age).
S100A6 and MMP9 showed significant positive correlation with OSDI and fluorescein staining and negative 
correlation with TBUT and Schirmer I test (Table 5). Similarly, S100A6 and MMP9 biomarkers positively cor-
related with each other. CST4 protein negatively correlated with fluorescein staining. There was no correlation 
between the biomarkers and the age of patients.
Discussion
In our MS-based proteomic study, we first compared tear samples of DE and MGD patients with control tear 
samples. The following proteins were mostly overexpressed in DE: C3, S100A6, S100A8, CP, APOD, ORM2, 
TXN, IGHG1, PLA2G2A, SERPINA1, and SLPI. These proteins are involved in biological processes related to 
the defense response, inflammatory process, and response to wounding. Among these proteins, TXN, IGHG1, 
PLA2G2A, SERPINA1, and SLPI were most downregulated in MGD.
Module # Biological process
# proteins from 
Module FDR Nodes
1
inflammatory response 6 <1.000E-03 IL6, TNF, S100A8, RELA, S100A9, S100A12
positive regulation of chemokine production 3 <3.333E-04 IL6, TNF, TLR4
response to lipopolysaccharide 4 2.50E-04 IL6, S100A8, S100A9, TLR4
cytokine-mediated signaling pathway 3 1.06E-03 IL6, RELA, STAT3
extrinsic apoptotic signaling pathway 2 9.44E-04 TNF, TRADD
acute-phase response 2 4.03E-03 IL6, STAT3
cell redox homeostasis 2 4.26E-03 IL6, TXN
innate and humoral immune response 4 5.80E-03 RELA, TXN, TLR4, S100A12
positive regulation of JNK cascade 2 4.20E-02 TNF, TLR4
cellular defense response 2 4.73E-02 LGALS3BP, RELA
2
extracellular matrix organization 5 <5.000E-04 MMP9, TIMP2, MMP2, MMP1, TIMP1
collagen catabolic process 3 3.33E-04 MMP9, MMP2, MMP1
response to cytokine stimulus 3 3.00E-03 JUN, SERPINE1, TIMP1
angiogenesis 4 2.67E-03 IL8, JUN, MMP2, ANXA2
aging 3 1.26E-02 JUN, IL1B, TIMP1
response to hypoxia 2 1.30E-02 MMP9, SERPINE1
negative regulation of cell proliferation 4 1.22E-02 IL8, JUN, IL1B, TIMP2
neutrophil chemotaxis 2 1.63E-02 IL8, IL1B
cellular response to interleukin-1 2 1.49E-02 IL8, MMP9
response to hypoxia 3 1.72E-02 MMP9, IL1B, MMP2
3
defense response to bacterium 4 3.52E-03 PLA2G2A, CST4, LCN1, LTF
positive regulation of inflammatory response 5 4.73E-03 C3, APOD, ORM1, ORM2, PLA2GSA
4
signal transduction 4 1.90E-03 S100A6, S100A11, ANXA1, S100A10
apoptosis 4 1.82E-03 S100A6, S100A11, ANXA1, S100A10
fibroblast proliferation 4 3.74E-03 S100A6, S100A11, ANXA1, S100A10
Table 4. Involvement of each module in different biological processes, showing the proteins implicated in each 
process42. FDR = False discovery rate.
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The most representative overexpressed proteins in the MGD group were ANXA1, CLU, ORM1, and LPO; the 
LPO protein had its lowest expression level in the DE group. These proteins are implicated mainly in apoptosis, 
oxidative stress, immune response, and keratinocyte differentiation, which represent some of the principal pro-
cesses involved in ocular surface diseases45. A panel of TXN, IGHG1, PLA2G2A, SERPINA1, SLPI, and LPO pro-
teins could unequivocally discriminate between DE and MGD as, according to our observations, their regulatory 
trends in these disease groups are opposite.
TXN is implicated in immune response, cell proliferation, cell–cell signaling, and oxidation–reduction pro-
cesses46. IGHG1 is associated with immune response47, and PLA2G2A is involved in the defense and inflamma-
tory responses and lipid catabolic processes48. SERPINA1 is involved in acute-phase response, proteolysis and 
platelet activation49, and SLPI, in the defense response50. The increased expression of these proteins in DE and the 
reduction of their levels in MGD suggest an enhanced activation of defense response, inflammatory, proteolytic, 
or cell–cell signaling processes triggered by a decrease in tear production.
In contrast, LPO is associated with the response to oxidative stress51. The direct relationship between hyper-
osmolarity and oxidative stress has been described by Zhang et al.52. Gaffney et al.53 have predicted substantially 
higher levels of hyperosmolarity in evaporative DE than in aqueous-deficient DE condition, which might explain 
the high expression levels of LPO protein in MGD group in comparison with DE. This observation and the spatial 
separation of MGD and DE groups in the canonical discriminant analysis, seen here suggest a different activation 
of osmolarity compensatory mechanisms, depending on the typology of dry eye.
In summary, the changes in regulatory processes in which these proteins are involved (such as endopeptidase 
activity, response to bacteria, acute-phase response, cell–cell signaling, or response to oxidative stress) might be 
the key biological events which distinguish DE from MGD. Validation of those candidate protein biomarkers in 
new tear samples will be a target of further studies.
Figure 4. Antibody microarrays. (A) Spotting pattern for the 12-subarray format. (B) Representative image 
of the arrays showing the distribution of the standard calibration curve and samples. Each microarray slide 
contains a standard calibration curve (left column) and the fluorescence acquisition for 5 tear samples. 
Fluorescence scans of the microarray multiplex assays were acquired at 633 nm.
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In contrast, the expression of another group of proteins was significantly downregulated in both pathologies: 
PROL1, SCGB1D1, SCGB2A1, LCN1, CST4, PIP, DCD, PROL3, LGALS3BP, LACRT, and PRR4. Most of these 
are proteins secreted by the lacrimal and Meibomian glands54,55. Taking into account the main functions of these 
proteins, this result suggests an association of the secretory deficiency of aqueous-deficient DE or obstructive 
MGD with a decreased antibacterial activity, which could increase a risk of ocular infection. Some of these pro-
teins, such as CST4, LCN1, SCGB2A1, and PIP, have also been downregulated in a previous study reported by 
our group24. Clustering analysis revealed that this protein group, characterized by a reduction in their expression 
levels, could be used to discriminate between DE and MGD.
We also found a very significant separation between the control and DE groups, with MGD occupying an 
intermediate position between these two groups (as presented in Fig. 2). Interestingly, a similar behavior was 
observed by our research group in a recent study56, in which we compared the conjunctival epithelium proteomes 
Figure 5. Comparison of the concentrations of candidate biomarkers in control (CT) and dry eye (DE) groups, 
measured using the customized antibody microarrays. Concentration is expressed in ng/mL. Green circles 
represent the mean concentration for the group. (A) Whisker plot of protein S100A6 concentrations. (B) 
Whisker plot of protein MMP9 concentrations. (C) Whisker plot of protein CST4 concentrations. (D) ROC 
curve analysis obtained by logistic regression using the three candidate biomarkers.
Variables S100A6 MMP9 CST4 OSDI TBUT Schirmer Fluorescein Age
S100A6 1
MMP9 0.4643 1
CST4 −0.1601 0.1108 1
OSDI 0.3616 0.3861 −0.0771 1
TBUT −0.7439 −0.6303 0.0431 −0.2816 1
Schirmer −0.5290 −0.4459 0.0800 −0.6099 0.5456 1
Fluorescein 0.5108 0.5983 −0.3481 0.4303 −0.5310 −0.5179 1
Age 0.1708 0.2136 −0.1605 0.4733 −0.1092 −0.3065 0.4478 1
Table 5. Pearson correlation matrix for biomarker concentrations and clinical parameters. Significant 
correlations are indicated in bold (p-value < 0.05).
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of DE, MGD, and CT individuals. In that work, we observed, based on a group of 17 proteins, a clear separation 
between DE and CT groups, with MGD in an intermediate position, closest to the CT group. These independent 
results from tear and epithelium analysis support the hypothesis that tear proteome alterations accompany the 
changes in conjunctival epithelium.
Apart from the unclear etiology of the studied pathologies, the heterogeneity of the reported results constitutes 
another key challenge in proteomic studies of complex diseases. Several factors can affect the results obtained for 
the tear proteome, including the tear collection method and sample storage29, analytical methods30, and differ-
ences in the patient inclusion and exclusion criteria. To validate a robust biomarker, it is of paramount importance 
to establish its reproducibility using several different technological approaches. To achieve this, we compared 
our results with those obtained in other proteomic tear studies. Tear samples used in these studies, representing 
the same pathologies, have been analyzed using 2D-PAGE24,28,57, SELDI-TOF profiling20, MS-based quantifica-
tion approaches7–9,14,17,19,23,25,26,28,58–60, or ELISA assays61–63. The comparison revealed discrepancies between the 
results of different studies, probably caused by some of the previously mentioned factors. However, the proteins 
whose expression behavior is similar in different studies acquire greater weight in terms of their robustness as 
biomarkers. Thus, despite the differences in the analytical technologies employed, we found a group of proteins 
whose expression was consistently upregulated in the DE group, in comparison with the controls, in the cited 
studies (S100A8, S100A6, C3, CP, ORM2, IGHG1, SERPINA1, ANXA1, CLU, and ORM17–9,14,20,23,24,26,28,58–63). 
Similarly, we found another group of proteins with reduced expression levels in the pathological groups, including 
PIP, proline-rich family (PROL1, PROL3, PRR4), SCGB1D1, CST4, LACRT, and LCN17–9,14,17,20,24–26,28,57,60. The 
proteins whose expression behavior is consistent in different studies are listed in Table 6.
The proteins S100A6, ANXA1, and CST4 are particularly noteworthy as molecular markers. Apart from their 
consistent expression behavior in various studies, their validity has been already confirmed using absolute quan-
tification in ELISA assays with independent samples24. That validation study has been conducted using 44 indi-
viduals for a biomarker discovery pipeline and 100 for validation. The study has shown a correct assignment of 
97.9% in sample classification for a panel of five markers (S100A6, ANXA1, CST4, PLAA, and ANXA11), with a 
precision of 93.5% for the first three markers. These results confirm the validity of these biomarkers.
Our study also found novel markers associated with ocular surface disorders: APOD, TXN, PLA2G2A, SLPI, 
LPO, LGALS3BP, and DCD.
Label-free approaches are increasingly considered advantageous and reliable since no additional chemi-
cal manipulation is needed. These proteomic methods have gained popularity due to their compatibility with 
high-throughput systems, their speed, and good reproducibility in the complex peptide mixture analyses6. 
Spectral-counting-based quantification is more reproducible and has a larger dynamic range than other label-free 
quantification methods64. However, in spectral-counting proteomics, physicochemical properties of the peptides 
can affect MS detection. This might result in imprecise results due to errors in the number of repeat observations 
of MS/MS spectra of the peptides. Therefore, we applied a peptide-specific normalization factor, which depends 
on peptide detection probability and improves the accuracy and reproducibility of the analysis65,66.
Complex diseases constitute intricate systems of altered biological processes. The study of systems biology 
using functional interaction networks reveals the changes triggered by various stressors (evaporation, osmolar-
ity, hyposecretion) and the molecular machinery that produces the diseases. Clusters of highly interconnected 
nodes can be seen within the functional interaction networks; these are often the protein complexes involved in 
pathways with a high probability of being regulated by the same mechanisms67. Our analysis of the functional 
network revealed five modules implicated in biological processes such as defense, inflammatory and acute-phase 





















Table 6. Proteins with expression profiles similar to those in other studies.
www.nature.com/scientificreports/
1 2Scientific RePoRTS | 7: 17478  | DOI:10.1038/s41598-017-17536-2
responses, response to wounding, response to lipopolysaccharide, T cell secretory granule organization, apop-
tosis, oxidative stress, extracellular matrix organization, signal transduction, keratinocyte differentiation, and 
fibroblast proliferation. Similar results of DE tear proteomics analyses have been reported in other studies24,31,45. 
In addition, we identified the most essential nodes as a function of their topological characteristics within the net-
work and their interconnectivity with other nodes68. These essential central nodes in the network may provide a 
detailed insight into the functions involved and their relationships. Our results indicate that DE and MGD share a 
functional interaction network in which the proteins JUN, RELA, STAT3, TLR4, ESR1, MMP9, GNAI3, ANXA1, 
and TIMP1 behave as principal nodes. These proteins are implicated in biological processes such as adherens 
junction processes, Wnt signaling pathways, cell–cell communication, and signal transduction. These processes 
appear to be associated with the very nature of the studied pathologies45.
Using a second, independent analytical method, we confirmed the results of the mass spectrometry analysis 
for two proteins (S100A6 and CST4). We also included a third potential biomarker inferred from the network 
analysis (MMP9), a principal node, which has often been reported as related to DE disease69–73.
To select the candidate biomarkers to validate in our study, we considered statistical significance (FDR), 
upregulation and downregulation fold-change, biomarkers representing different physiological processes (biolog-
ical significance), number of replications (number of studies detecting a significant change), and the value of the 
protein in the previously reported panels of biomarkers or clinical trials. The S100A6 and CST4 proteins selected 
in our MS/MS study comply with the established criteria. One of these biomarkers was upregulated (S100A6), 
and one, downregulated (CST4). They are involved in different physiological processes (S100A6 participates in 
calcium binding/epithelial integrity and growth and CST4, in cysteine protease inhibitor/antimicrobial activity).
S100A6 has the most significant FDR. Although this protein showed only an intermediate fold-change value 
in this study, in our previous report using 2D-PAGE24, its fold-change was high (8.5). It has a suitable number of 
replicates (number of studies reporting similar changes): three in unbiased mass spectrometry screenings (US) 
and one validation in candidate immuno-detection study (CA)74. This protein has been included in a panel of DE 
biomarkers24. In addition, S100A6 has been used for monitoring the response of patients to changing glaucoma 
treatment from preserved latanoprost to preservative-free tafluprost. The increase in the level of tear S100A6 in 
patients treated with preserved latanoprost was reduced a year after switching to preservative-free tafluprost75, 
suggesting the potential application of this protein not only as a diagnostic but also as a prognostic biomarker (as 
in cases of topical drug-induced DE)76. In this study, CST4 showed a significant (but intermediate-level) FDR and 
fold-change. However, in our previous analysis using 2D-PAGE, we have found a 4.6-fold change for this pro-
tein24. In addition, CST4 has a considerable number of replicates: five in unbiased mass spectrometry screenings 
(US) and one validation in a candidate immuno-detection (CA)74. It has been included in a panel of DE biomark-
ers24. Finally, the two biomarkers, when used together as panel, have shown correct assignment (CA) of 86% in 
the diagnosis and classification of patients (unpublished data).
The MMP9 protein has been found in candidate immuno-detection and activity detection (CA) studies but 
not in unbiased mass spectrometry screening74. We selected this biomarker in our network analysis because 
of the nine proteins identified as central nodes, MMP9 was the protein best represented in modules (Table 4). 
Accordingly, the top proteins in the central nodes, in decreasing order of interaction networks (5, 4, 3, and 2), 
were: MMP9 (module 2) in 5 biological processes (BP); RELA and TRL4 (both in module 1) in 4 BP; ANXA 1 
(module 4) and JUN and TIMP1 (module 2) in 3 BP; and STAT 3 (module 1) in 2 BP. Moreover, in module 2, 
MMP9 was the main player in the nodes with the most significant FDR.
The microarrays were specifically designed for 1-microliter tear sample analysis. The standardization of the 
miniaturized immunoassays had included several important steps. We selected the high-affinity compatible anti-
body pairs (using SPR and sandwich ELISA assays) and chose appropriate slide surfaces for the linkage of capture 
antibodies. We experimentally determined the incubation times and washing and blocking buffers. We also per-
formed cross-reactivity studies to assure specificity of the assays and adjusted the calibration curves to clinically 
relevant concentration ranges (unpublished data).
The results of microarray analysis corroborated the proteomic results obtained using mass spectrometry and 
network analysis inference. They were comparable with the results of a study previously published by our group, 
in which these biomarkers were examined using commercially available ELISA kits24. The ROC curve values in 
the two studies are similar. Here, the results showed a high degree of correlation between the biomarkers and the 
clinical data, which is essential when considering a biomarker as surrogate endpoint77. However, there was no 
correlation with the age of patients, indicating that the biomarkers are valid for any age range.
Taking into account the scarcity of tear samples (only a few microliters can be obtained from each patient), the 
microarray technology is a promising alternative to other proteomic techniques for simultaneous protein/peptide 
quantification. Another important advantage of this technique is that a large number of proteins can be examined 
at the same time. Multifactorial pathologies such as DE are complex and involve many proteins and biological 
processes; a simultaneous analysis of multiple proteins in the same sample can provide a broad overview of the 
changes in protein expression during disease development.
We are currently evaluating the selected biomarkers (using multiplexed quantification techniques) in new tear 
samples obtained from different pathologies.
In summary, we performed a study of differential protein expression in DE and MGD disorders, using quan-
titative proteomics based on label-free MS. We studied the behavior of these two pathologies, from a biolog-
ical perspective, using functional interaction networks. The analysis revealed nine central nodes, represented 
by the MMP9, JUN, RELA, STAT3, TLR4, ESR1, GNAI3, ANXA1, and TIMP1 proteins. These essential nodes 
might determine the biological functions to be studied in the future. Such studies should help to understand 
the diverse pathologies and accelerate the development of new effective therapeutic agents and strategies. Our 
comparison with the results obtained using different proteomic technologies corroborated our candidates for 
stable and robust molecular markers of the studied diseases. Among these, the S100A6 and CST4 proteins are 
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some of the most noteworthy. They are now confirmed by orthogonal validation using ELISA24 and the custom-
ized microarray assays employed here. Thus, they are validated using two different technologies, in different 
tear samples and in independent assays. Finally, we explored the correlation of selected biomarkers with clinical 
parameters, obtaining good correlation levels and confirming the validity of these proteins as tear biomarkers for 
DE. However, additional coordinated interlaboratory validation should be conducted to test the potential tear 
biomarkers in different populations.
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